Project Grant R43HL162109

Award Date 2/11/22
Completion Date 2/10/23
Dollars Obligated $856K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Webster, TX, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $1,024,635 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and improve quality of life for patients with heart failure, a condition affecting over 6.5 million Americans. The key innovation is a hybrid magnetically levitated blood pump...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,643 to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed for efficient low blood flow rates needed to treat pediatric and neonatal patients. The key objectives are to design, develop, and test a low-flow ECMO pump capable of operating at 0.05 to 0.5 L/min (50 to 500 cc/min) to...
Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $676,970 to the Geisinger Clinic in Danville, PA to investigate the effects of continuous versus pulsatile blood flow on blood trauma, arterial remodeling, and vasoregulation in a chronic bovine model using the BiVACOR total artificial heart. The research aims to determine if pulsatile flow can reduce adverse events associated with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), provides $870,467 to Ension Inc. to develop an innovative Bearingless Flux Reversal Motor (FRM) for a Pediatric Cardiopulmonary Assist System (PCAS). The goal is to extend the operating range of the FRM motor to accommodate the high pressure and low flow requirements for neonatal and infant patients weighing between 5-15 kg. The PCAS system is comprised of a...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $615,370 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a featherweight, pulse-driven micropump for continuous drug delivery. The project aims to characterize the infusion rate capabilities of a prototype pulse-driven micropump, and then optimize the design to...
The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $413,595 to Unandup, LLC to develop a magnetic rotational atherectomy platform for treating coronary lesions and cardiovascular disease. The project aims to create an over-the-wire atherectomy device controlled by magnetic fields, which can safely and effectively debulk severely calcified lesions to enable percutaneous coronary...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $294,063 to Biomembretics, Inc. to develop and demonstrate high-volume manufacturing of a biomimetic microfluidic oxygenator for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a safer and simpler alternative to the current standard of invasive mechanical ventilation, which carries...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $790,738 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Circulatech LLC, a for-profit limited liability company located in Pembroke Pines, Florida. The grant will fund the development and evaluation of Circulatech's Thoraflush, a proactive chest tube system that utilizes dual irrigation technology to maintain drainage patency and prevent...
This $499,103 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting Alleviant Medical, Inc.'s efforts to advance the commercial readiness of their no-implant interatrial shunt therapy for treating heart failure. The key objectives are to implement high-volume manufacturing capabilities, establish production readiness for the ALV1 system, and execute reimbursement and marketing...

DEVELOPMENT OF A MINIMALLY INVASIVE PARTIAL CIRCULATORY SUPPORT DEVICE FOR CHRONIC USE - PROJECT SUMMARY THE NAUTILUS PUMP IS A CENTRIFUGAL, TOTALLY IMPLANTABLE, COMPACT, LONG-LASTING PARTIAL CIRCULATORY ASSIST DEVICE IMPLANTED VIA A MINIMALLY INVASIVE PACEMAKER POCKET APPROACH TO SUPPORT LV FUNCTION FOR LATE-STAGE HEART FAILURE INTERVENTION. THE NAUTILUS PUMP WILL BE CONNECTED TO THE SYSTEMIC CIRCULATION BY ATTACHMENT OF THE PUMP'S INFLOW PORT TO A CANNULA PLACED INTO THE SUBCLAVIAN VEIN AND POSITIONED IN THE LEFT ATRIUM VIA A TRANSSEPTAL APPROACH, AND THE OUTFLOW PORT TO A VASCULAR GRAFT ANASTOMOSED TO THE SUBCLAVIAN ARTERY. THIS REVOLUTIONARY PARTIAL SUPPORT PUMP IS BEING DESIGNED TO ELIMINATE THE NEED FOR INVASIVE TECHNIQUES TO IMPLANT FULL SUPPORT DEVICES (STERNOTOMY OR THORACOTOMY) AND ELIMINATE THE NEED FOR PERCUTANEOUS CABLES AND/OR DRIVELINES. THE NAUTILUS PUMP AND SYSTEM WILL BE A MINIMALLY INVASIVE, LOW ENERGY CONSUMPTION SYSTEM THAT WILL NOT IMPOSE EXCESSIVE AFTERLOAD ON THE LV, THEREFORE MAINTAINING PULSATILITY. FURTHERMORE, IT WILL RETAIN NATIVE HEART VENTRICULAR MUSCLE INTEGRITY, OFFERING THE BEST ENVIRONMENT FOR LV RECONDITIONING. ANOTHER FEATURE TO BE INTEGRATED TO THE PUMP IS THE NEXT-GENERATION TRANSCUTANEOUS ENERGY TRANSFER (TET) SYSTEM, WHICH DOES NOT REQUIRE DIRECT EXTERNAL COIL SKIN CONTACT TO POWER THE PUMP. THIS IS A REMARKABLE FEATURE THAT IS NOT PRESENT IN ANY OTHER COMPETITORS' SYSTEMS. LEVERAGING PUMP AFFINITY LAWS, WHICH GOVERN CENTRIFUGAL PUMP PERFORMANCE AND ARE USEFUL TO MODIFY PUMPS FOR NEW AND DIFFERENT REQUIRED DUTIES, AND THE COMPANY'S EXTENSIVE INTELLECTUAL PROPERTY PORTFOLIO, THE NAUTILUS PUMP IS BEING DESIGNED BASED ON OUR FULL SUPPORT ASSIST PUMP. IT WILL COMBINE PERMANENT MAGNETIC LEVITATION WITH A LOW SHEAR HYDRODYNAMIC BEARING TO PRODUCE AN ULTRA-LOW POWER CONSUMPTION PUMP THAT STILL RETAINS THE SUPERIOR BLOOD HANDLING CHARACTERISTICS OF FULL MAGLEV TECHNOLOGY. THIS HIGHLY EFFICIENT PUMP IS THEN COMBINED WITH IMPLANTABLE GRADE BATTERIES AND A LIGHT, EXTERNAL MOBILE WIRELESS POWER SOURCE, MAKING IT A TOTALLY IMPLANTED AND WIRELESSLY POWERED SYSTEM THAT DOES NOT REQUIRE A PERCUTANEOUS DRIVELINE, DIRECT SKIN CONTACT, OR BULKY EXTERNAL BATTERIES. IN-VIVO PRELIMINARY STUDIES USING THE FULL CIRCULATORY SUPPORT PUMP DEVICE VALIDATED ALL THE INNOVATIVE FEATURES IN THIS GRANT PROPOSAL, SUCH AS A HIGH-EFFICIENCY PUMP WITH A LOW HEMOLYSIS RATE. THIS SBIR PHASE I PROPOSED GRANT OBJECTIVES ARE ADDRESSED IN TWO SPECIFIC AIMS THAT WILL BE EXECUTED FOR EIGHT MONTHS. IN AIM 1, THE NAUTILUS PUMP WILL BE DESIGNED, AND A PROTOTYPE IS FABRICATED TO ACCOMMODATE 2 - 3 L/MIN FLOWS AT PHYSIOLOGIC PRESSURES. IN AIM 2, IN-VITRO STUDIES, USING A RECIRCULATING BLOOD TEST LOOP, WILL BE PERFORMED TO DETERMINE RED BLOOD CELL HEMOLYSIS, PLATELET AND LEUKOCYTE ACTIVATION, VWF DEGRADATION, AND FUNCTION, AS WELL AS OVERALL BLOOD HEMOSTATIC POTENTIAL, COMPARED TO OUR FULL CIRCULATORY SUPPORT PUMP AND THE BPX-80 BIO PUMP (MEDTRONIC - MINNEAPOLIS, MN, US). THE CONCLUSION OF THE PROPOSED AIMS WILL DEMONSTRATE THE FEASIBILITY AND HEMOCOMPATIBILITY OF THE NAUTILUS PUMP DESIGN. IT WILL SET THE STAGE FOR A PHASE II SBIR GRANT APPLICATION WHERE THE PERFORMANCE, SAFETY, AND SUITABILITY OF THE DEVICE WILL BE EVALUATED IN AN IN-VIVO SETTING, IN ADDITION TO THE DEVELOPMENT OF A TRANSEPTAL CANNULA.

Posted 2/11/22, 12:00 AM